• Topics

  • Formats

Organiser: Pharmaphorum

Biologics now represent around 40% of all pharmaceutical spending in Europe, and they’ve played a major role in transforming treatment outcomes in key disease areas such as cancer, autoimmune disorders, and diabetes. However, the complexity and cost of biologic development can challenge healthcare system sustainability, which can potentially delay timely and equitable access for patients.

Reading this content is completely free

Enjoy Unlimited Access and Unlock
Additional Features with a Free Account

Join Now

You are attempting to log out of MyMA

Do you really want to log out?